Skip to main content
SpringerLink
Log in

Genetic risk and protective factors for the idiopathic inflammatory myopathies

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The idiopathic inflammatory myopathies, or myositis syndromes, are heterogeneous autoimmune diseases defined by chronic muscle inflammation of unknown cause. They likely develop after the interaction of genetic and environmental risk factors in the absence of protective factors. The known genetic risk and protective factors are common alleles at polymorphic immune response loci and vary depending on phenotype. Furthermore, genetic associations are stronger with phenotypes defined by clinical features and autoantibodies than with myositis patients as a whole. Genetic factors for myositis also vary by age of onset, ethnicity, and environmental exposure group. Of interest, risk genes for one phenotype are often protective for another, possibly explaining the mutual exclusivity of many myositis subgroups. International collaborations using genome-wide association studies are needed to identify additional genes, gene-gene, and gene-environment interactions, all of which have pathogenic, therapeutic, and preventative implications for these increasingly recognized disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Miller FW: Inflammatory myopathies: polymyositis, dermatomyositis, and related conditions. In Arthritis and Allied Conditions: A Textbook of Rheumatology, edn 15. Edited by Koopman W, Moreland L. Philadelphia: Lippincott, Williams, and Wilkins; 2004:1593–1620.

    Google Scholar 

  2. Oddis CV, Rider LG, Reed AM, et al.: International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005, 52:2607–2615.

    Article  PubMed  Google Scholar 

  3. Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1997, 27:343–356.

    Article  Google Scholar 

  4. Nagaraju K, Rider LG, Fan C, et al.: Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis 2006, 3:2.

    Article  PubMed  CAS  Google Scholar 

  5. Engel AG, Arahata K: Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986, 17:704–721.

    Article  PubMed  CAS  Google Scholar 

  6. Hohlfeld R, Engel AG, Goebels N, Behrens L: Cellular immune mechanisms in inflammatory myopathies. Curr Opin Rheumatol 1997, 9:520–526.

    Article  PubMed  CAS  Google Scholar 

  7. O’Hanlon TP, Dalakas MC, Plotz PH, Miller FW: Predominant TCR-alpha beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994, 152:2569–2576.

    PubMed  Google Scholar 

  8. O’Hanlon TP, Messersmith WA, Dalakas MC, et al.: Gamma delta T cell receptor gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. Clin Exp Immunol 1995, 100:519–528.

    Article  PubMed  Google Scholar 

  9. Love LA, Leff RL, Fraser DD, et al.: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360–374.

    CAS  Google Scholar 

  10. Miller FW: Myositis-specific autoantibodies. Touchstones for understanding the inflammatory myopathies. JAMA 1993, 270:1846–1849.

    Article  PubMed  CAS  Google Scholar 

  11. Ollier B: The genetic basis of rheumatic disease. In Rheumatology, edn 3. Edited by Hochberg MC. London: Mosby; 2003:99–111.

    Google Scholar 

  12. O’Hanlon TP, Carrick DM, Arnett FC, et al.: Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians. Medicine (Baltimore). 2005, 84:338–349.

    Article  Google Scholar 

  13. Chinoy H, Salway F, Fertig N, et al.: In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2005, 8:R13.

    Article  CAS  Google Scholar 

  14. Mamyrova G, O’Hanlon TP, Monroe JB, et al.: Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. Arthritis Rheum 2006, 54:3979–3987.

    Article  PubMed  CAS  Google Scholar 

  15. O’Hanlon TP, Carrick DM, Targoff IN, et al.: Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 2006, 85:111–127.

    Article  CAS  Google Scholar 

  16. Targoff IN, Mamyrova G, Trieu EP, et al.: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006, 54:3682–3689.

    Article  PubMed  CAS  Google Scholar 

  17. Betteridge ZE, Gunawardena H, Chinoy H, et al.: Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann Rheum Dis 2008 Oct 17 (Epub ahead of print).

  18. Needham M, James I, Corbett A, et al.: Sporadic inclusion body myositis: phenotypic variability and influence of HLADR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry 2008, 79:1056–1060.

    Article  PubMed  CAS  Google Scholar 

  19. O’Hanlon TP, Rider LG, Mamyrova G, et al.: HLA polymorphisms in African Americans with idiopathic inflammatory myopathy: allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. Arthritis Rheum 2006, 54:3670–3681.

    Article  PubMed  CAS  Google Scholar 

  20. Furuya T, Hakoda M, Tsuchiya N, et al.: Immunogenetic features in 120 Japanese patients with idiopathic inflammatory myopathy. J Rheumatol 2004, 31:1768–1774.

    PubMed  CAS  Google Scholar 

  21. Zhai N, Zhang Q, Han X, Song F: Association of HLADRB1 alleles with polymyositis/dermatomyositis in northern Chinese Hans. Chin Med Sci J 2002, 17:198.

    PubMed  Google Scholar 

  22. Rider LG, Shamim E, Okada S, et al.: Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American whites: a tale of two loci. Arthritis Rheum 1999, 42:1285–1290.

    Article  PubMed  CAS  Google Scholar 

  23. Shamim EA, Rider LG, Pandey JP, et al.: Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum 2002, 46:1885–1893.

    Article  PubMed  Google Scholar 

  24. Miller FW: Myositis. In Contemporary Targeted Therapies in Rheumatology, edn 1. Edited by Smolen J, Lipsky P. London: Informa Healthcare; 2007:467–484.

    Google Scholar 

  25. Pachman LM, Liotta-Davis MR, Hong DK, et al.: TNFal-pha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum 2000, 43:2368–2377.

    Article  PubMed  CAS  Google Scholar 

  26. Hassan AB, Nikitina-Zake L, Sanjeevi CB, et al.: Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum 2004, 50:1013–1015.

    Article  PubMed  CAS  Google Scholar 

  27. Chinoy H, Salway F, John S, et al.: Tumour necrosis factor-alpha single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies. Rheumatology (Oxford) 2007, 46:1411–1416.

    Article  CAS  Google Scholar 

  28. Mamyrova G, O’Hanlon TP, Sillers L, et al.: Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum 2008, 58:3941–3950.

    Article  PubMed  CAS  Google Scholar 

  29. Hassan AB, Fathi M, Dastmalchi M, et al.: Genetically determined imbalance between serum levels of tumour necrosis factor (TNF) and interleukin (IL)-10 is associated with anti-Jo-1 and anti-Ro52 autoantibodies in patients with poly- and dermatomyositis. J Autoimmun 2006, 27:62–68.

    Article  PubMed  CAS  Google Scholar 

  30. Vang T, Miletic AV, Arimura Y, et al.: Protein tyrosine phosphatases in autoimmunity. Annu Rev Immunol 2008, 26:29–55.

    Article  PubMed  CAS  Google Scholar 

  31. Chinoy H, Platt H, Lamb JA, et al.: The protein tyrosine phosphatase N22 gene is associated with juvenile and adult idiopathic inflammatory myopathy independent of the HLA 8.1 haplotype in British Caucasian patients. Arthritis Rheum 2008, 58:3247–3254.

    Article  PubMed  CAS  Google Scholar 

  32. Walsh RJ, Kong SW, Yao Y, et al.: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007, 56:3784–3792.

    Article  PubMed  CAS  Google Scholar 

  33. Baechler EC, Bauer JW, Slattery CA, et al.: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007, 13:59–68.

    Article  PubMed  CAS  Google Scholar 

  34. O’Hanlon TP, Rider LG, Schiffenbauer A, et al.: Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum 2008, 58:3239–3246.

    Article  PubMed  Google Scholar 

  35. Lettre G, Rioux JD: Autoimmune diseases: insights from genome-wide association studies. Hum Mol Genet 2008, 17:R116–R121.

    Article  PubMed  CAS  Google Scholar 

  36. Hirsch TJ, Enlow RW, Bias WB, Arnett FC: HLA-D related (DR) antigens in various kinds of myositis. Hum Immunol 1981, 3:181–186.

    Article  PubMed  CAS  Google Scholar 

  37. Arnett FC, Targoff IN, Mimori T, et al.: Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum 1996, 39:1507–1518.

    Article  PubMed  CAS  Google Scholar 

  38. Reed AM, Pachman LM, Hayford J, Ober C: Immunogenetic studies in families of children with juvenile dermatomyositis. J Rheumatol 1998, 25:1000–1002.

    PubMed  CAS  Google Scholar 

  39. Wedderburn LR, McHugh NJ, Chinoy H, et al.: HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 2007, 46:1786–1791.

    Article  CAS  Google Scholar 

  40. Rider LG, Gurley RC, Pandey JP, et al.: Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. Arthritis Rheum 1998, 41:710–719.

    Article  PubMed  CAS  Google Scholar 

  41. West JE, Reed AM: Analysis of HLA-DM polymorphism in juvenile dermatomyositis (JDM) patients. Hum Immunol 1999, 60:255–258.

    Article  PubMed  CAS  Google Scholar 

  42. Reed AM, Stirling JD: Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol 1995, 44:131–135.

    Article  PubMed  CAS  Google Scholar 

  43. Friedman JM, Pachman LM, Maryjowski ML, et al.: Immunogenetic studies of juvenile dermatomyositis: HLA-DR antigen frequencies. Arthritis Rheum 1983, 26:214–216.

    Article  PubMed  CAS  Google Scholar 

  44. Tomono N, Mori M, Nakajima S, et al.: HLA-DRB1*15021 is the predominant allele in Japanese patients with juvenile dermatomyositis. J Rheumatol 2004, 31:1847–1850.

    PubMed  CAS  Google Scholar 

  45. Chinoy H, Salway F, John S, et al.: Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. Ann Rheum Dis 2007, 66:970–973.

    Article  PubMed  CAS  Google Scholar 

  46. Rider LG, Artlett CM, Foster CB, et al.: Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000, 121:47–52.

    Article  PubMed  CAS  Google Scholar 

  47. Werth VP, Berlin JA, Callen JP, et al.: Mannose binding lectin (MBL) polymorphisms associated with low MBL production in patients with dermatomyositis. J Invest Dermatol 2002, 119:1394–1399.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institute of Environmental Health Sciences, National Institutes of Health, 9 Memorial Drive, Room 1W101, MSC 0958, Bethesda, MD, 20892, USA

    Terrance P. O’Hanlon

Authors
  1. Terrance P. O’Hanlon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederick W. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terrance P. O’Hanlon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Hanlon, T.P., Miller, F.W. Genetic risk and protective factors for the idiopathic inflammatory myopathies. Curr Rheumatol Rep 11, 287–294 (2009). https://doi.org/10.1007/s11926-009-0040-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0040-2

Keywords

Search

Navigation